A Phase 2/3 interventional study of Pridopidine and Matching Placebo in Amyotrophic Lateral Sclerosis, sponsored by Merit E. Cudkowicz, MD. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-23.
Sponsored by Merit E. Cudkowicz, MD · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States — 98 open to participants now, 129 under way, 11 of them phase 3. Amyotrophic Lateral Sclerosis · United States.
Among the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, this one is the 47th largest by enrollment of the 307 interventional ones that give a count, is one of 29 that started in 2020, is one of 18 in phase 2/3, and was the 279th registered.
981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.
Browse Amyotrophic Lateral Sclerosis studies →98 of the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States are open now. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 18–80
Cognixion · Sites in United States
Ages 18+
Johns Hopkins University · Sites in United States
Ages 18+ · Healthy volunteers
Neuralink Corp · Sites in United States
Ages 18+
Biogen · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
440 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 89 · Phase 2 139 · Phase 3 48 · Phase 4 1
First in 1982; this study’s year is marked. 29 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 163 is above the median of 38 across 664 interventional studies indexed under Amyotrophic Lateral Sclerosis.
Median enrollment 33 across the 307 interventional studies, 100 across the 121 observational. Of the 277 that completed or were terminated, 102 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
163 of 440 have an industry lead sponsor. The 10 most frequent:
Merit E. Cudkowicz, MD is the lead sponsor of 9 studies on the registry; none are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 7 (100%) have results posted.
Merit E. Cudkowicz, MD has 9 studies filed under Amyotrophic Lateral Sclerosis — fewer than ten, so there is no comparison to draw.
41 of the studies in Amyotrophic Lateral Sclerosis with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07161999Phase 3Coya TherapeuticsStudy of COYA 302 for the Treatment of ALS | 2027-04 |
| NCT04057898Phase 3MediciNovaEvaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS | 2027-04 |
| NCT04297683Phase 3Merit E. Cudkowicz, MDHEALEY ALS Platform Trial - Master Protocol | 2027-07 |
| NCT07410806Phase 3Merit E. Cudkowicz, MDHEALEY ALS Platform Trial - Regimen I NUZ-001 | 2027-07-01 |
| NCT04220190Phase 3Rapa Therapeutics LLCRAPA-501 Therapy for ALS | 2027-07-01 |
Add all 41 to your calendar (.ics) → With an account.
Among the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.
Regimen D will evaluate the safety and efficacy of a single study drug, pridopidine, in participants with ALS.
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. This trial is designed as a perpetual platform trial. This means that there is a single Master Protocol dictating the conduct of the trial. The HEALEY ALS Platform Trial Master Protocol is registered as NCT04297683.
Once a participant enrolls into the Master Protocol and meets all eligibility criteria, the participant will be eligible to be randomized into any currently enrolling regimen. All participants will have an equal chance of being randomized to any currently enrolling regimen.
If a participant is randomized to Regimen D Pridopidine, the participant will complete a screening visit to assess additional Regimen D eligibility criteria. Once Regimen D eligibility criteria are confirmed, participants will complete a baseline assessment and be randomized in a 3:1 ratio to either active pridopidine or matching placebo.
Regimen D will enroll by invitation, as participants may not choose to enroll in Regimen D. Participants must first enroll into the Master Protocol and be eligible to participate in the Master Protocol before being able to be randomly assigned to Regimen D.
For a list of enrolling sites, please see the HEALEY ALS Platform Trial Master Protocol under NCT04297683.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The following exclusion criteria are in addition to the exclusion criteria specified in the Master Protocol (NCT NCT04297683).
Participants using the following medications at the time of the Regimen Specific Screening Visit:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pridopidine is administered orally twice daily for 24 weeks.
Drug: Pridopidine
Matching placebo is administered orally twice daily for 24 weeks.
Drug: Matching Placebo
Administration: Oral Dose: 45mg twice daily
Administration: Oral Dose: one capsule twice daily
Disease Progression as Assessed by the ALSFRS-R Total Score
Change in disease severity over time as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R). Each type of function is scored from 4 (normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0. Patients with higher scores have more physical function.
Time frame: Baseline to 24 Weeks
Mortality Event Rate
Mortality is defined as death or death equivalent. A participant is determined to meet the criteria of death equivalent if permanent assisted ventilation (PAV) is used for more than 22 hours per day for more than seven days in a row. The rate of mortality was estimated from a Bayesian shared-parametric model that assumed exponentially distributed survival times.
Time frame: Baseline to 24 Weeks
Change in Bulbar Function in Participants With Bulbar Dysfunction at Baseline
Change in bulbar function over time in participants with bulbar dysfunction at baseline as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) bulbar subdomain. Each question is scored from 4 (normal) to 0 (no ability), with a maximum total score of 12 and a minimum total score of 0 for the bulbar subdomain. Patients with higher scores have more bulbar function. Participants were classified as having bulbar dysfunction at baseline if their score on the ALSFRS-R bulbar domain (Q1-Q3) score was less than 12.
Time frame: Baseline to 24 Weeks
Bulbar Function in All Randomized Participants
Change in bulbar function over time in all randomized participants as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) bulbar subdomain. Each question is scored from 4 (normal) to 0 (no ability), with a maximum total score of 12 and a minimum total score of 0 for the bulbar subdomain. Patients with higher scores have more bulbar function.
Time frame: Baseline to 24 Weeks
Respiratory Function
Change in respiratory function over time as measured by Slow Vital Capacity (SVC).
Time frame: Baseline to 24 Weeks
Bulbar Function in Participants With Rapid Pre-baseline Progression
Change in bulbar function over time in participants with rapid pre-baseline progression as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) bulbar subdomain. Each question is scored from 4 (normal) to 0 (no ability), with a maximum total score of 12 and a minimum total score of 0 for the bulbar subdomain. Patients with higher scores have more bulbar function. Participants were classified with rapid pre-baseline progression if their change in ALSFRS-R total score between Master Protocol Screening and Regimen Baseline was greater than or equal or 0.75 points per month.
Time frame: Baseline to 24 Weeks
Time to Bulbar Decline
Time to first decline of 1-point or greater post baseline in the ALSFRS-R bulbar domain score among all participants. Analysis performed using interval-censored survival analysis. Results presented as median interval (upper \& lower bounded) time to event.
Time frame: Baseline to 24 Weeks
Muscle Strength
Change in muscle strength over time as measured isometrically using hand-held dynamometry (HHD).
Time frame: Baseline to 24 Weeks
Number of Participants That Experienced Death or Death Equivalent
The number of participants who died or met the criterion for a death equivalent from the date of their baseline visit to the end of the Week 24visit window (generally 175 days after baseline). The death equivalent criterion is use of permanent assisted ventilation (PAV) for more than 22 hours per day for more than 7 days in a row.
Time frame: Baseline to 24 Weeks
| Milestone | Pridopidine | Matching Placebo |
|---|---|---|
| Started | 120 | 42 |
| Completed | 96 | 38 |
| Not completed | 24 | 4 |
Change in disease severity over time as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R). Each type of function is scored from 4 (normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0. Patients with higher scores have more physical function.
| points per month | Pridopidine | Matching Placebo |
|---|---|---|
| Disease Progression as Assessed by the ALSFRS-R Total Score | -0.99 ± 0.077 | -1.00 ± 0.070 |
Mortality is defined as death or death equivalent. A participant is determined to meet the criteria of death equivalent if permanent assisted ventilation (PAV) is used for more than 22 hours per day for more than seven days in a row. The rate of mortality was estimated from a Bayesian shared-parametric model that assumed exponentially distributed survival times.
| events per month | Pridopidine | Matching Placebo |
|---|---|---|
| Mortality Event Rate | 0.012 ± 0.0029 | 0.012 ± 0.0029 |
Change in bulbar function over time in participants with bulbar dysfunction at baseline as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) bulbar subdomain. Each question is scored from 4 (normal) to 0 (no ability), with a maximum total score of 12 and a minimum total score of 0 for the bulbar subdomain. Patients with higher scores have more bulbar function. Participants were classified as having bulbar dysfunction at baseline if their score on the ALSFRS-R bulbar domain (Q1-Q3) score was less than 12.
| point change from baseline | Pridopidine | Matching Placebo |
|---|---|---|
| Change in Bulbar Function in Participants With Bulbar Dysfunction at Baseline | -1.78 ± 0.261 | -1.69 ± 0.210 |
Change in bulbar function over time in all randomized participants as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) bulbar subdomain. Each question is scored from 4 (normal) to 0 (no ability), with a maximum total score of 12 and a minimum total score of 0 for the bulbar subdomain. Patients with higher scores have more bulbar function.
| point change from baseline | Pridopidine | Matching Placebo |
|---|---|---|
| Bulbar Function in All Randomized Participants | -1.16 ± 0.169 | -1.25 ± 0.141 |
Change in respiratory function over time as measured by Slow Vital Capacity (SVC).
| percent change | Pridopidine | Matching Placebo |
|---|---|---|
| Respiratory Function | -8.81 ± 1.351 | -8.35 ± 1.132 |
Change in bulbar function over time in participants with rapid pre-baseline progression as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) bulbar subdomain. Each question is scored from 4 (normal) to 0 (no ability), with a maximum total score of 12 and a minimum total score of 0 for the bulbar subdomain. Patients with higher scores have more bulbar function. Participants were classified with rapid pre-baseline progression if their change in ALSFRS-R total score between Master Protocol Screening and Regimen Baseline was greater than or equal or 0.75 points per month.
| points change from baseline | Pridopidine | Matching Placebo |
|---|---|---|
| Bulbar Function in Participants With Rapid Pre-baseline Progression | -1.54 ± 0.297 | -1.54 ± 0.302 |
Time to first decline of 1-point or greater post baseline in the ALSFRS-R bulbar domain score among all participants. Analysis performed using interval-censored survival analysis. Results presented as median interval (upper \& lower bounded) time to event.
| days | Pridopidine | Matching Placebo |
|---|---|---|
| Lower Bound of Interval | 84 (53 to 141) | 66 (56 to 105) |
| Upper Bound of Interval | 86 (83 to 141) | 77 (68 to 115) |
Change in muscle strength over time as measured isometrically using hand-held dynamometry (HHD).
| percent change | Pridopidine | Matching Placebo |
|---|---|---|
| Muscle Strength | -26.74 ± 2.556 | -24.97 ± 2.123 |
The number of participants who died or met the criterion for a death equivalent from the date of their baseline visit to the end of the Week 24visit window (generally 175 days after baseline). The death equivalent criterion is use of permanent assisted ventilation (PAV) for more than 22 hours per day for more than 7 days in a row.
| Participants | Pridopidine | Matching Placebo |
|---|---|---|
| Number of Participants That Experienced Death or Death Equivalent | 5 | 6 |
Collected over Up to 35 weeks after participant signed Master Protocol consent.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pridopidine | 2/120 (1.7%) | 16/121 (13.2%) | 106/121 (87.6%) |
| Matching Placebo | 0/42 (0%) | 3/41 (7.3%) | 37/41 (90.2%) |
| Event | Pridopidine | Matching Placebo |
|---|---|---|
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 3/121 | 1/41 |
| Ankle fractureInjury, poisoning and procedural complications | 0/121 | 1/41 |
| SepsisInfections and infestations | 0/121 | 1/41 |
| Amyotrophic lateral sclerosisNervous system disorders | 2/121 | 0/41 |
| SyncopeNervous system disorders | 2/121 | 0/41 |
| Atrial fibrillationCardiac disorders | 2/121 | 0/41 |
| Cerebellar strokeNervous system disorders | 1/121 | 0/41 |
| Ischaemic strokeNervous system disorders | 1/121 | 0/41 |
| PresyncopeNervous system disorders | 1/121 | 0/41 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/121 | 0/41 |
| Event | Pridopidine | Matching Placebo |
|---|---|---|
| Muscular weaknessNervous system disorders | 29/121 | 13/41 |
| FallInjury, poisoning and procedural complications | 34/121 | 12/41 |
| NeuromyopathyNervous system disorders | 24/121 | 3/41 |
| ConstipationGastrointestinal disorders | 14/121 | 8/41 |
| DiarrhoeaGastrointestinal disorders | 15/121 | 4/41 |
| NauseaGastrointestinal disorders | 15/121 | 3/41 |
| DysphagiaGastrointestinal disorders | 13/121 | 5/41 |
| FatigueGeneral disorders | 12/121 | 5/41 |
| COVID-19Infections and infestations | 12/121 | 4/41 |
| DysarthriaNervous system disorders | 10/121 | 4/41 |
Baseline Analysis Population includes only placebo participants from the Regimen D Efficacy Regimen Only (ERO) sample; shared placebo participants from other regimens are not included in the Baseline Analysis Population.
| Age, Continuous(years) | Pridopidine | Matching Placebo | Total |
|---|---|---|---|
| Mean | 57.9 ± 10.10 | 57.1 ± 9.86 | 57.7 ± 10.01 |
| Sex: Female, Male(Participants) | Pridopidine | Matching Placebo | Total |
|---|---|---|---|
| Female | 48 | 9 | 57 |
| Male | 72 | 33 | 105 |
| Ethnicity (NIH/OMB)(Participants) | Pridopidine | Matching Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 11 | 1 | 12 |
| Not Hispanic or Latino | 107 | 41 | 148 |
| Unknown or Not Reported | 2 | 0 | 2 |
| Race (NIH/OMB)(Participants) | Pridopidine | Matching Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 5 | 1 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 7 | 2 | 9 |
| White | 105 | 39 | 144 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 2 | 0 | 2 |
| El Escorial Diagnosis(Participants) | Pridopidine | Matching Placebo | Total |
|---|---|---|---|
| Clinically Definite ALS | 50 | 18 | 68 |
| Clinically Probable ALS | 40 | 12 | 52 |
| Clinically Probable ALS - Laboratory Supported | 22 | 5 | 27 |
| Clinically Possible ALS | 8 | 7 | 15 |
| ALS Onset Location(Participants) | Pridopidine | Matching Placebo | Total |
|---|---|---|---|
| Axial | 1 | 2 | 3 |
| Bulbar | 23 | 10 | 33 |
| Generalized | 2 | 0 | 2 |
| Limb | 93 | 30 | 123 |
| Multiple | 1 | 0 | 1 |
| Baseline Edaravone Use Flag(Participants) | Pridopidine | Matching Placebo | Total |
|---|---|---|---|
| No | 92 | 32 | 124 |
| Yes | 28 | 10 | 38 |
| Baseline Riluzole Use Flag(Participants) | Pridopidine | Matching Placebo | Total |
|---|---|---|---|
| No | 30 | 9 | 39 |
| Yes | 90 | 33 | 123 |
10 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2020 to primary completion in Jul 2022, 18 months.
Results were first posted in Aug 2023, 1 year 1 month after primary completion.
Of 22 phase 2/3 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 109. This study's 18 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pridopidine
Amyotrophic Lateral Sclerosis →
Merit E. Cudkowicz, MD